- SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to Outperform from Market Perform on attractive risk-reward following shares’ underperformance relative to larger cap oligo therapy peers.
- SVB Securities raised the price target to $35 from $21, implying a 33% upside from Tuesday’s close.
- Also Read: JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals.
- The analyst notes that Arrowhead stock lost around 35% YTD, underperforming the peers such as Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY), Ionis Pharmaceuticals Inc (NASDAQ:IONS), and Moderna Inc (NASDAQ:MRNA).
- “This leaves ARWR trading at ~$2.8B market cap, a discount to the $3.3B at which Dicerna was acquired by Novo Nordisk,” (NYSE:NVO), the analyst writes, referring to the most recent benchmark for upside M&A optionality in this subsector.
- SVB analyst says the appetizing risk/reward profile sets as the company heads into upcoming data catalysts for the pulmonary portfolio and upside optionality from potential out-licensing/partnership of pipeline assets.
- Price Action: ARWR shares are up 10.22% at $28.91 on the last check Wednesday.
Apple Faces Headwinds In China: iPhone Sales Down As Huawei Thrives
Apple has experienced a decline in iPhone sales in China, facing strong competition from Huawei, which has made a significant comeback in the market, amidst heightened U.S.-China tensions and Apple's efforts to diversify its manufacturing base.
